Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO...

Area of Science:

• Cardiology
• Biochemistry
• Preventive Medicine

Background:

• Bloodstream cholesterol, particularly LDL-C, is a key factor in atherosclerotic cardiovascular diseases.
• LDL-C has been the primary biomarker and therapeutic target for lipid-lowering treatments for decades.
• Residual cardiovascular risk persists even with LDL-C-targeted therapies.

Purpose of the Study:

• To discuss the limitations of standard LDL-C assessment methods.
• To highlight the role of non-HDL-C as a superior predictor and therapeutic target.
• To emphasize the persistent cardiovascular risk in patients with uncontrolled non-HDL-C.

Main Methods:

• Review of current literature on lipid biomarkers and cardiovascular risk.
• Analysis of the predictive value of LDL-C versus non-HDL-C.
• Discussion of therapeutic implications for lipid-lowering strategies.

Main Results:

• Standard LDL-C assessment has limitations.
• Non-HDL-C demonstrates greater reliability in predicting atherosclerotic disease, especially in specific patient groups.
• Patients with controlled LDL-C but uncontrolled non-HDL-C exhibit higher cardiovascular risk.

Conclusions:

• Non-HDL-C is a more effective biomarker for predicting atherosclerotic cardiovascular disease risk.
• Non-HDL-C should be considered a primary therapeutic target for lipid-lowering treatments.
• Refining preventive strategies by targeting non-HDL-C can improve patient outcomes and reduce residual risk.